Influenza A (H5N1) pandemic prototype vaccine Fluval®

Expert Review of Vaccines

Volumn 8, Issue 5, 2009, Pages 619-624

  Vajo, Zoltan ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

H5N1; Influenza; Pandemic; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; FLUVAL; INFLUENZA VACCINE; OIL; UNCLASSIFIED DRUG; WATER; ALUMINUM DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; PHOSPHATE;

ADJUVANT THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEVER; GENETICS; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MORBIDITY; MORTALITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SHIVERING; SIDE EFFECT; SWEATING; SWELLING; VIRION; EPIDEMIC; HUNGARY; IMMUNOLOGY; INFLUENZA VIRUS A H5N1;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; DISEASE OUTBREAKS; HUMANS; HUNGARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PHOSPHATES; VACCINES, INACTIVATED;

EID: 65649135422     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.25     Document Type: Review

References (42)

1. Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352(4), 333-340 (2005).
2. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg. Infec. Dis. 13(9), 1348-1353 (2007). (Pubitemid 47510296)
3. Poland GA. Vaccines against avian influenza - a race against time. N. Engl. J. Med. 354(13), 1411-1413 (2006).
4. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005). (Pubitemid 41817715)
5. Carrat F, Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine 25(39-40), 6852-6862 (2007). (Pubitemid 47398929)
6. Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24(44-46), 6588-6593 (2006). (Pubitemid 46107146)
7. Girard M, Palkonyay L, Kieny MP. Report of the 4th meeting on the 'Evaluation of pandemic influenza prototype vaccines in clinical trials' WHO, Geneva, Switzerland, 14-15 February 2008. Vaccine 26(39), 4975-4977 (2008). • Report of the WHO meeting on H5N1 vaccine development.
8. Takatsy G. Purified precipitated virus obtained by a new simple method. Acta Med. Acad. Sci. Hung. 3(2), 185-191 (1952).
9. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96). EMEA, 12 March (1997).
10. Vajo Z, Kosa L, Szilvasy I et al. Yearly licensing studies from 1997-2007 of the inactivated whole virus seasonal influenza vaccine Fluval - a useful approach to pandemic vaccine development even in less well developed countries? Influenza Other Respir. Viruses 2(6), 211-218 (2008).
11. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). EMEA, 5 April (2004).
12. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23(22), 2943-2952 (2005). (Pubitemid 40386496)
13. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactiyated whole virus and subunit vaccines. J. Biol. Stand. 5(3), 237-247 (1977). (Pubitemid 8143405)
14. European Directoriate for the Quality Medicines. European Pharmacopia, 5.8 CD, 7/2007 Strasbourg, France, 3406-3407 (2007).
15. Vajo Z, Kosa L, Visontay I et al. Inactivated whole virus influenza A (H5N1) vaccine. Emerg. Infec. Dis. 13(5), 807-808 (2007). •• First clinical trial of Fluval, involving 146 patients. (Pubitemid 46698765)
16. Vajo Z, Kosa L, Szilvasy I et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr. Infect. Dis. J. 27(12), 1052-1056 (2008). •• First H5N1 vaccine trial in children.
17. Giesecke J, Sellwood C, Van-Tam J. Expert advisory groups on human H5N1 vaccines. European Centre for Disease Control and Prevention, Stockholm, Sweden, March 2007.
18. Fazekas G, Martosne-Mendi R, Jankovics I, Szilvasy I, Vajo Z. Cross-reactive immunity in adult and elderly patients against clade 2 influenza A H5N1 virus strains induced by Fluval, a reverse genetic-derived adjuvanted H5N1 clade 1 prototype pandemic influenza vaccine. Clin. Vaccine Immunol. 16, 437-443 (2008). •• First trial showing cross-reactive immunity against wild-type H5N1 virus strains.
19. Nicholson KG, Tyrrell DAJ, Harrison P et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J. Biol. Stand. 7(2), 123-136 (1979). (Pubitemid 9149059)
20. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006). •• First published H5N1 vaccine trial.
21. Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004(H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657-1664 (2006).
22. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007). (Pubitemid 47247854)
23. Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole- virion influenza A (H5N1) vaccine: a Phase I randomized controlled trial. Lancet 368(9540), 991-997 (2006). (Pubitemid 44353667)
24. Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573-2584 (2008).
25. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357(9272), 1937-1943 (2001). (Pubitemid 32568336)
26. Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197(5), 667-675 (2008).
27. Rümke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine 26(19), 2378-2388 (2008).
28. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J. Infect. Dis. 194(Suppl. 2), S111-S118 (2006). (Pubitemid 44630954)
29. Engler RJ, Nelson MR, Klote MM et al.; Walter Reed Health Care System Influenza Vaccine Consortium. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch. Intern. Med. 168(22), 2405-2414 (2008).
30. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic Nature 442(7101), 448-452 (2006). (Pubitemid 44264793)
31. Friede M, Serdobova I, Palkonyay L, Kieny MP. Technology transfer hub for pandemic influenza vaccine. Vaccine 27(5), 631-632 (2009).
32. Murakami S, Iwasa A, Iwatsuki-Horimoto K et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26(50), 6398-6404 (2008).
33. Nolan TM, Richmond PC, Skeljo MV et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26(33), 4160-4167 (2008).
34. Nolan T, Richmond PC, Formica NT et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26(50), 6383-6391 (2008).
35. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191(8), 1210-1215 (2005). (Pubitemid 40503646)
36. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J. Infect. Dis. 197(4), 580-583 (2008).
37. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO www.who.int/csr/disease/avian-influenza/country/cases-table- 2009-03-02/en/index.html
38. Congressional Budget Office. A potential influenza pandemic: possible macroeconomic effects and policy issues www.dhhs.state.nh.us/DHHS/CDCS/LIBRARY/ Research/avian-cbo-economy.htm
39. US FDA. Draft guidance on clinical data needed to support the licensure of pandemic influenza vaccines www.fda.gov/cber/gdlns/panfluvac.htm
40. WHO. Avian influenza: assessing the pandemic threat www.who.int/csr/ disease/influenza/H5N1-9reduit.pdf
41. Wood J. Update on development of international standards for H5N1 antibodies. WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trial, 14-15 February 2008 www.who.int/vaccine-research/diseases/ influenza/WoodJ-infleunza-meeting-140208.pdf
42. WHO and manufacturers move ahead with plans for H5N1 influenza global vaccine stockpile www.who.int/mediacentre/news/statements/2007/s14/en/index.html